Meta-analysis of Randomized Controlled Trials of Bosentan for Treatment of Pulmonary Arterial Hypertension

Overview

Journal Korean J Intern Med

Specialty General Medicine

Date 2013 Dec 6

PMID 24307846

Citations 6

Authors

Young Ho Lee

Gwan Gyu Song

Affiliations

Soon will be listed here.

Abstract

Background/aims: We assessed the efficacy and safety of bosentan in patients with pulmonary arterial hypertension (PAH).

Methods: We surveyed randomized controlled trials (RCTs) of the efficacy and safety of bosentan in patients with PAH using MEDLINE, EMBASE, the Cochrane Controlled Trials Register, and manual searches. Meta-analysis of RCTs was performed to determine treatment efficacy and safety outcomes. Results are presented as odds ratios (ORs) or weighted mean differences (WMDs).

Results: Meta-analysis of seven RCTs including a total of 410 patients and 296 controls revealed that the 6-minute work distance was significantly higher in the bosentan group than in the placebo group (WMD, 46.19; 95% confidence interval [CI], 21.20 to 71.19; p = 2.9 × 10(-5)). Compared with the placebo, bosentan significantly reduced the mean pulmonary arterial pressure in patients with PAH (WMD, -6.026; 95% CI, -8.785 to -3.268, p = 1.8 × 10(-6)). The bosentan therapy group worsened less clinically than the placebo group (OR, 0.252; 95% CI, 0.140 to 0.454; p = 4.6 × 10(-7)). The incidence of serious adverse events did not differ between the bosentan and placebo groups (OR, 0.948; 95% CI, 0.556 to 1.614; p = 0.843). However, the results of the abnormal liver function test (LFT) were significantly higher in the bosentan group than in the placebo group (OR, 2.312; 95% CI, 1.020 to 5.241; p = 0.045).

Conclusions: This meta-analysis shows that bosentan can treat PAH effectively. However, bosentan increased the incidence of abnormal LFT results compared with the placebo.

Citing Articles

Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis.

Cao F, Wu K, Zhu Y, Jiang J, Zhang G, Liu J Front Cardiovasc Med. 2023; 9:1055897.

PMID: 36712266 PMC: 9875131. DOI: 10.3389/fcvm.2022.1055897.

Chronic thromboembolic pulmonary hypertension: a review.

Chong C, Tay E, Sia C, Poh K Singapore Med J. 2021; 62(7):318-325.

PMID: 34409465 PMC: 8801849. DOI: 10.11622/smedj.2021089.

Epigenetic Regulation of Pulmonary Arterial Hypertension-Induced Vascular and Right Ventricular Remodeling: New Opportunities?.

Kocken J, da Costa Martins P Int J Mol Sci. 2020; 21(23).

PMID: 33255338 PMC: 7727715. DOI: 10.3390/ijms21238901.

Diagnosis of Pulmonary Arterial Hypertension in Children by Using Cardiac Computed Tomography.

Chen S, Huang J, Lee W, Lin M, Chen Y, Wang J Korean J Radiol. 2019; 20(6):976-984.

PMID: 31132823 PMC: 6536789. DOI: 10.3348/kjr.2018.0673.

Matrix Metalloproteinase 1 Causes Vasoconstriction and Enhances Vessel Reactivity to Angiotensin II via Protease-Activated Receptor 1.

Nugent W, Mishra N, Strauss 3rd J, Walsh S Reprod Sci. 2015; 23(4):542-8.

PMID: 26438597 PMC: 5933188. DOI: 10.1177/1933719115607998.

References

Sitbon O, Humbert M, Jais X, Ioos V, Hamid A, Provencher S . Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111(23):3105-11. DOI: 10.1161/CIRCULATIONAHA.104.488486. View

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M . A randomised, controlled trial of bosentan in severe COPD. Eur Respir J. 2008; 32(3):619-28. DOI: 10.1183/09031936.00011308. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Valerio G, Bracciale P, Grazia DAgostino A . Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2009; 3(1):15-21. DOI: 10.1177/1753465808103499. View

Barst R, Langleben D, Badesch D, Frost A, Lawrence E, Shapiro S . Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006; 47(10):2049-56. DOI: 10.1016/j.jacc.2006.01.057. View

Davie N, Haleen S, Upton P, Polak J, Yacoub M, Morrell N . ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002; 165(3):398-405. DOI: 10.1164/ajrccm.165.3.2104059. View

He B, Zhang F, Li X, Tang C, Lin G, Du J . Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J. 2010; 74(7):1458-64. DOI: 10.1253/circj.cj-09-0971. View

Galie N, Hinderliter A, Torbicki A, Fourme T, Simonneau G, Pulido T . Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003; 41(8):1380-6. DOI: 10.1016/s0735-1097(03)00121-9. View

10.

Provencher S, Sitbon O, Simonneau G . Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. Expert Opin Pharmacother. 2005; 6(8):1337-48. DOI: 10.1517/14656566.6.8.1337. View

11.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

12.

Egger M, Smith G, Phillips A . Meta-analysis: principles and procedures. BMJ. 1998; 315(7121):1533-7. PMC: 2127925. DOI: 10.1136/bmj.315.7121.1533. View

13.

Jais X, DArmini A, Jansa P, Torbicki A, Delcroix M, Ghofrani H . Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008; 52(25):2127-34. DOI: 10.1016/j.jacc.2008.08.059. View

14.

Galie N, Manes A, Branzi A . The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004; 61(2):227-37. DOI: 10.1016/j.cardiores.2003.11.026. View

15.

Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G . Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008; 371(9630):2093-100. DOI: 10.1016/S0140-6736(08)60919-8. View

16.

Galie N, Beghetti M, Gatzoulis M, Granton J, Berger R, Lauer A . Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006; 114(1):48-54. DOI: 10.1161/CIRCULATIONAHA.106.630715. View

17.

Lee Y, Rho Y, Choi S, Ji J, Song G . Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int. 2006; 27(2):157-61. DOI: 10.1007/s00296-006-0175-7. View

18.

Davey Smith G, Egger M . Meta-analyses of randomised controlled trials. Lancet. 1997; 350(9085):1182. DOI: 10.1016/s0140-6736(05)63833-0. View

19.

Nath S, Harley J, Lee Y . Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Hum Genet. 2005; 118(2):225-34. DOI: 10.1007/s00439-005-0044-6. View

20.

Humbert M, Barst R, Robbins I, Channick R, Galie N, Boonstra A . Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004; 24(3):353-9. DOI: 10.1183/09031936.04.00028404. View